Add event to my calendar
January 28, 2015
Bookmark and Share

Second International conference: The Pharmaceutical Industry and the Fight Against Doping in Sport

Tokyo, Japan

Organised by

Ministry of Education, Culture, Sports, Science and Technology (MEXT) of Japan
UNESCO
World Anti-Doping Agency (WADA)
Japan Anti-Doping Agency (JADA)

Supported by

International Federation of Pharmaceutical Manufacturers & Associations (IFPMA)
The Federation of Pharmaceutical Manufacturers' Associations of JAPAN (FPMAJ)
Japan Pharmaceutical Manufacturers Association (JPMA)

Programme

Opening

  • Mr. Hideki Niwa, State Minister of Education, Culture, Sports, Science and Technology (MEXT), Japan; Executive Committee member, World Anti-Doping Agency (WADA)
  • Sir. Craig Reedie, President, WADA 
  • Ms Angela Melo, Director, Ethics, Youth and Sport Division, Sector for Social and Human Sciences, UNESCO

Part 1: Societal and Economic Risks of Doping

  •     Mr. David Howman, Director General, WADA
  •     Dr. Tatsuya Kondo, Chief Executive, Pharmaceuticals and Medical Devices Agency (PMDA)
  •     Dr. Temo Waqanivalu, Team Leader, World Health Organization (WHO)
  •     Mr. Clément De Maillard, Criminal Intelligence Officer, INTERPOL

Part 2:  Challenges in Anti-Doping and Role of the Biopharmaceutical Industry

  •     Dr. Valérie Fourneyron, Chair of Health, Medical & Research Committee, WADA
  •     Dr. Steven Elliott, Scientific Executive Director (retired), Amgen  
  •     Mr. Masafumi Nogimori, Vice President IFPMA, President FPMAJ

Part 3: Biopharmaceutical Industry and Anti-Doping Authorities: Expectations and Perspectives for the future

Conclusions and Perspectives

  • Sir. Craig Reedie, President, WADA

Second Session – From Concepts to Achievements to Progressing Partnerships for Clean Sport and Society

Round Table 1 – From the political concept to developing partnerships: what kind of network to build and how to include all the stakeholders?
Moderator: Prof. Hidenori Suzuki, President, Japan Anti-Doping Agency (JADA)  
Rapporteur: Mr. Marcellin Dally, Secretary, Anti-Doping Convention Youth and Sport Section Division of Ethics, Youth and Sport, UNESCO

Panelists
Ms. Barbara Leishman, Chair, Anti-Doping Working Group, IFPMA
Mr. David Verbraska, Vice President, Pfizer
Mr. Haruhiko Hirate, Corporate Officer, Takeda Pharmaceutical Company Ltd. 
Mr Michael K Gottlieb, National Program Director, White House Drug Policy Office, Executive Office of the President, USA

Round table 2 – Effective collaboration between the World Anti-Doping Agency and the Biopharmaceutical Industry
Moderator: Ms. Barbara Leishman, Chair, Anti-Doping Working Group, IFPMA
Rapporteur: Dr. Steven Elliott, Scientific Executive Director (retired), Amgen

Panelists
Mr. Mark Luttmann, WADA Cooperation Coordinator, GlaxoSmithKline
Mr.  Christian de la Tour, VP Corporate Projects, Public Affairs & Corporate Communications, Ipsen
Mr. Tatsuya Kamiuchi, Group Manager, Drug Safety Division, Chugai Pharmaceutical Co., Ltd.
Dr. Olivier Rabin, Senior Director, Science, WADA

Concluding Remarks: How to further develop co-operation in the future?
General Rapporteurs
Mr. Masafumi Nogimori, Vice President IFPMA, President FPMAJ
Mr. David Howman, Director General, WADA
Prof. Ichiro Kono, President, Japan Sport Council, Vice-President, Tokyo 2020, JADA Board member